Courses

← vista completa

Published on July 1, 2006 | http://doi.org/10.5867/medwave.2006.06.3384

Polycystic ovary syndrome and endometrial cancer: a bibliographic review

Síndrome de ovario poliquístico y cáncer de endometrio: revisión bibliográfica

Alejandra Villavicencio Galdeano

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

Alejandra Villavicencio Galdeano

Programa de Doctorado en Ciencias Biomédicas, Escuela de Postgrado, Facultad de Medicina de la Universidad de Chile, Santiago, Chile

Figures

Article has no figures.

Forum

No messages

History

Citation Villavicencio Galdeano A. Polycystic ovary syndrome and endometrial cancer: a bibliographic review. Medwave 2006;6(06):e3384 doi: 10.5867/medwave.2006.06.3384

Submission date 01/01/1970

Acceptance date 01/01/1970

Publication date 01/07/2006

Index

Metrics

Not available at the moment.

Notes

References

  1. Legro RS, Spielman R, Urbanek M, Driscoll D, Strauss JF, Dunaif A. Phenotype and genotype in polycystic ovary syndrome. Recent Prog Horm Res. 1998;53:217-56. | PubMed
  2. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004 Jan;81(1):19-25. | CrossRef | PubMed
  3. Homburg R. Polycystic ovary síndrome-from gynaecological curiosity to multisystem endocrinopathy. Hum Reprod. 1996 Jan;11(1):29-39. | PubMed
  4. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obst Gynecol 1935;(29):181-191.
  5. Okon MA, Laird SM, Tuckerman EM and Li T-C. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function. Fertil Steril 69:682-690, 1998 | CrossRef
  6. Sagle M, Bishop K, Ridley N, Alexander FM, Michel M, Bonney RC, et al. Recurrent early miscarriage and polycystic ovaries. BMJ. 1988 Oct 22;297(6655):1027-8. | CrossRef | PubMed
  7. Chamlain DL, Taylor HB. Endometrial hyperplasia in young women. Obstet Gynecol. 1970 Nov;36(5):659-66. | PubMed
  8. Cheung AP. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstet Gynecol. 2001 Aug;98(2):325-31. | CrossRef | PubMed
  9. Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update. 2001 Nov-Dec;7(6):522-5. | CrossRef | PubMed
  10. Henderson BE, Casagrande JT, Pike MC, Mack T, Rosario I, Duke A. The epidemiologý of endometrial cancer in young women. Br J Cancer. 1983 Jun;47(6):749-56. | CrossRef | PubMed
  11. Elwood JM, Cole P, Rothman KJ, Kaplan SD. Epidemiology of endometrial cancer. J Natl Cancer Inst. 1977 Oct;59(4):1055-60. | PubMed
  12. Coulam CB, Annegers JF, Kranz JS. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol. 1983 Apr;61(4):403-7. | PubMed
  13. Lannigan DA. Estrogen receptor phosphorilation. Steroids. 2003 Jan;68(1):1-9. | CrossRef | PubMed
  14. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, et al. Human estrogen receptor beta-gene structure, chromosomal localization and expression pattern. J Clin Endocrinol Metab. 1997 Dec;82(12):4258-65. | CrossRef | PubMed
  15. Fujimoto J, Sakaguchi H, Aoki I, Toyoki H, Tamaya T. Clinical implications of the expression of estrogen receptor-a and -b in primary and metastatic lesions of uterine endometrial cancers. Oncology. 2002;62(3):269-77. | CrossRef | PubMed
  16. Villavicencio A, Goyeneche A, Telleria C, Bacallao K, Gabler F, Fuentes A, et al. Potential consequences of steroid environment in the development of endometrial hyperplasia in patients with polycystic ovarian syndrome. Gynecol Oncol. 2009 Oct;115(1):102-7. Epub 2009 Jul 23. | CrossRef | PubMed
  17. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 1990 May;9(5):1603-14. | PubMed
  18. Fujimoto J, Ichigo S, Hori M, Nishigaki M, Tamaya T. Expression of progesterone receptor form A and B mRNAs in gynecologic malignant tumors. Tumour Biol. 1995;16(4):254-60. | CrossRef | PubMed
  19. Maliqueo M, Clementi M, Gabler F, Johnson MC, Palomino A, Sir-Petermann T, et al. Expression of steroid receptors and proteins related to apoptosis in endometria of women with polycystic ovary syndrome. Fertil Steril. 2003 Sep;80 Suppl 2:812-9. | CrossRef | PubMed
  20. Vermeulen-Meiners C, Poortman J, Nabuurs M, Thijssen JH. The endogenous concentration and subcellular distribution of androgens in normal human premenopausal endometrium. Gynecol Endocrinol. 1988 Jun;2(2):121-30. | CrossRef | PubMed
  21. Horie K, Takakura K, Imai K, Liao S, Mori T. Immunohistochemical localization of androgen receptor in the human endometrium, deciduas, placenta and pathological conditions of the endometrium. Hum Reprod. 1992 Nov;7(10):1461-6. | PubMed
  22. Suri NK. Steroid content in endometrial tissue. East Afr Med J. 1997 Apr;74(4):242-8. | PubMed
  23. Kato J, Seto T. Correlation of androgen receptors with histological differentiation in human endometrial carcinomas. Acta Obstet Gynecol Scand. 1985;64(3):209-12 | CrossRef | PubMed
  24. Mertens HJ, Heineman MJ, Koudstaal J, Theunissen P, Evers JL. Androgen receptor content in human endometrium. Eur J Obstet Gynecol Reprod Biol. 1996 Dec;70(1):11-3. | CrossRef | PubMed
  25. Fujimoto J, Nishigaki M, Hori M, Ichigo S, Itoh T, Tamaya T. The effect of estrogen and androgen on androgen receptors and mRNA levels in uterine leiomyoma, myometrium and endometrium of human subjects. J Steroid Biochem Mol Biol. 1994 Aug;50(3-4):137-43. | CrossRef | PubMed
  26. Lovely LP, Appa Rao KB, Gui Y, Lessey BA. Characterization of the androgen receptor in a well-differentiated endometrial adenocarcinoma cell line (Ishikawa). J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):235-41. | CrossRef | PubMed
  27. Slayden OD, Nayak NR, Burton KA, Chwalisz K, Cameron ST, Critchley HO, et al. Progesterone antagonists increase androgen receptor expression in the rhesus macaque and human endometrium. J Clin Endocrinol Metab. 2001 Jun;86(6):2668-79. | CrossRef | PubMed
  28. Apparao KB, Lovely LP, Gui Y, Lininger RA, Lessey BA. Elevated endometrial androgen receptor expression in women with polycystic ovary syndrome. Biol Reprod. 2002 Feb;66(2):297-304. | CrossRef | PubMed
  29. Prodi G, Nicoletti G, De Giovanni C, Galli MC, Grilli S, Nanni P, et al. Multiple steroid hormone receptors in normal and abnormal human endometrium. J Cancer Res Clin Oncol. 1980;98(2):173-83. | CrossRef | PubMed
  30. Shibata H, Spencer TE, Oñate SA, Jenster G, Tsai SY, Tsai MJ, et al. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog Horm Res. 1997;52:141-64; discussion 164-5. | PubMed
  31. Torchia J, Glass C, Rosenfeld MG. Co-activators and co-repressors in the integration of transcriptional responses. Curr Opin Cell Biol. 1998 Jun;10(3):373-83. | CrossRef | PubMed
  32. Parker MG. Transcriptional activation by oestrogen receptors. Biochem Soc Symp. 1998;63:45-50. | PubMed
  33. Kershah SM, Desouki MM, Koterba KL, Rowan BG. Expression of estrogen receptor coregulators in normal and malignant human endometrium. Gynecol Oncol. 2004 Jan;92(1):304-13. | CrossRef | PubMed
  34. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, et al. Steroid receptor co-activator-1 is a histone acetyltransferase. Nature. 1997 Sep 11;389(6647):194-8. | CrossRef | PubMed
  35. Chen H, Lin RJ,Schiltz RL, Chakravarti D, Nash A, Nagy L et al. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell. 1997 Aug 8;90(3):569-80. | CrossRef | PubMed
  36. Gregory CW, Wilson EM, Apparao KB, Lininger RA, Meyer WR, Kowalik A, et al. Steroid receptor coactivator expression throughout the menstrual cycle in normal and abnormal endometrium. J Clin Endocrinol Metab. 2002 Jun;87(6):2960-6. | CrossRef | PubMed
  37. Speroff L, Vande Wiele RL. Regulation of the human menstrual cycle. Am J Obstet Gynecol. 1971 Jan 15;109(2):234-47. | PubMed
  38. Tabibzadeh S. The signals and molecular pathways involved in human menstruation, a unique process of tissue destruction and remodeling. Mol Hum Reprod. 1996 Feb;2(2):77-92. | CrossRef | PubMed
  39. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002 Sep;3(9):565-74. | CrossRef | PubMed
  40. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000 Mar;13(3):295-308. | CrossRef | PubMed
  41. Boyd J. Estrogen as a carcinogen: the genetics and molecular biology of human endometrial carcinoma. Prog Clin Biol Res. 1996;394:151-73. | PubMed
  42. Jeyarajah A, Oram D, Jacobs I. Molecular events in endometrial carcinogenesis. Int J Gynecol Cancer 1996;6: 425-438. | CrossRef
  43. Villavicencio A, Gabler F, Fuentes A, Vega M. Regulators of cell survival in endometrium from patients with polycystic ovarian syndrome. 12th World Congress on Human Reproduction. Venecia, Italia, Marzo 2005.
  44. Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet. 2003 May 24;361(9371):1810-2. | CrossRef | PubMed
  45. American Collegeof Obstetricians and Gynecologists. ACOG Practice Bulletin. Polycystic ovary syndrome. Obstet Gynecol. 2002 Dec;100(6):1389-402. | CrossRef | PubMed
  46. Cory S, Vaux DL, Strasser A, Harris AW, Adams JM. Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res. 1999 Apr 1;59(7 Suppl):1685s-1692s. | PubMed
  47. Borner C, Monney L, Olivier R, Rosse J, Conus S and Fellay I. Bcl-2 and Bax: the good and the bad for the cell survival. Anticancer Res ;18 (Abstr. 15):4521.
  48. Kroemer G. The proto-oncogen bcl-2 and its role in regulating apoptosis. Nat Med. 1997 Jun;3(6):614-20. | CrossRef | PubMed
  49. Korsmeyer SJ. Bcl-2 gene family and the regulation of programmed cell death. Cancer Res. 1999 Apr 1;59(7 Suppl):1693s-1700s. | PubMed
  50. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, et al. Prevention of apoptosis by Bcl-2: release cytochrome c from mitochondria blocked. Science. 1997 Feb 21;275(5303):1129-32. | CrossRef | PubMed
  51. Lu QL, Poulsom R, Wong L, Hanby AM. Bcl-2 expression in adult and embryonic non-haematopoietic tissues. J Pathol. 1993 Apr;169(4):431-7. | CrossRef | PubMed
  52. Chan WK, Mole MM, Levison DA, Ball RY, Lu QL, Patel K, et al. Nuclear and cytoplasmic Bcl-2 expression in endometrial hyperplasia and adenocarcinoma. J Pathol. 1995 Nov;177(3):241-6. | CrossRef | PubMed
  53. Hockenbery DM. Bcl-2 in cancer, development and apoptosis. J Cell Sci Suppl. 1994;18:51-5. | PubMed
  54. Crescenzi E, Palumbo G. Bcl-2 exerts a pRb-mediated cell cycle inhibitory function in HEC1B endometrial carcinoma cells. Gynecol Oncol. 2001 May;81(2):184-92. | CrossRef | PubMed
  55. Otsuki Y, Misaki O, Sugimoto O, Ito Y, Tsujimoto Y, Akao Y. Cyclic Bcl-2 gene expresión in human uterine endometrium during the menstrual cycle. Lancet. 1994 Jul 2;344(8914):28-9. | CrossRef | PubMed
  56. Sakuragi N, Salah-eldin AE, Watari H, Itoh T, Inoue S, Moriuchi T, et al. Bax, Bcl-2 and p53 expression in endometrial cancer. Gynecol Oncol. 2002 Sep;86(3):288-96. | CrossRef | PubMed
  57. Sherr CJ. G1 phase progression: cyclin on cue. Cell. 1994 Nov 18;79(4):551-5. | CrossRef | PubMed
  58. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995 May 15;9(10):1149-63. | CrossRef | PubMed
  59. Nurse P. Ordering S phase and M phase in the cell cycle. Cell. 1994 Nov 18;79(4):547-50. | CrossRef | PubMed
  60. Sherr CJ. Mammalian G1cyclins. Cell. 1993 Jun 18;73(6):1059-65. | CrossRef | PubMed
  61. Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ, Arnold A. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev. 1999 Aug;20(4):501-34. | CrossRef | PubMed
  62. Quarmby VE, Korach KS. The influence of 17 beta-estradiol on patterns of cell division in the uterus. Endocrinology 114: 694-702, 1984 | CrossRef | PubMed
  63. Hata H, Hamano M, Watanabe J, Kuratomo H. Role of estrogen and estrogen-related growth factor in the mechanism of hormone dependency of endometrial carcinoma cells. Oncology. 1998 Dec;55 Suppl 1:35-44. | CrossRef | PubMed
  64. Kyushima N, Watanabe J, Hata H, Jobo T, Kameya T, Kuramoto H. Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables. J Cancer Res Clin Oncol. 2002 Jun;128(6):307-12. Epub 2002 Apr 10. | CrossRef | PubMed
  65. Weinberg RA. The retinobalstoma protein and cell cycle control. Cell. 1995 May 5;81(3):323-30. | CrossRef | PubMed
  66. Rubul Quddus M, Latkovich P, Castellano WJ, James Sung C, Steinhoff MM, Briggs RC, et al. Expression of cyclin D1 in normal, metaplasic, hyperplastic endometrium and endometrioid carcinoma suggests a role in endometrial carcinogenesis. Arch Pathol Lab Med. 2002 Apr;126(4):459-63. | PubMed
  67. Sherr CJ. Cancer cell cycles. Science. 1996 Dec 6;274(5293):1672-7. | CrossRef | PubMed
  68. Berchuck A. Biomarkers in the endometrium. J Cell Biochem Suppl. 1995;23:174-8. | CrossRef | PubMed
  69. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA,et al. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13513-8. | CrossRef | PubMed
  70. Weng LP, Brown JL and Eng C. PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet. 2001 Mar 15;10(6):599-604. | CrossRef | PubMed
  71. Guzeloglu-Kayisli O, Kayisli UA, Al-Rejjal R, Zheng W, Luleci G, Arici A. Regulation of PTEN (Phosphatase and tensin homolog deleted on chromosome 10) expresión by estradiol and progesterone in human endometrium. J Clin Endocrinol Metab. 2003 Oct;88(10):5017-26. | CrossRef | PubMed
  72. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997 Sep 15;57(18):3935-40. | PubMed
  73. Yoshinaga K, Sasano H, Furukawa T, Yamakawa H, Yuki M, Sato S, et al. The PTEN, BAX and IGFIIR genes are mutated in endometrial atypical hyperplasia. Jpn J Cancer Res. 1998 Oct;89(10):985-90. | CrossRef | PubMed
  74. Maxwell GL, Risinger JI, Gumbs C, Shaw H, Bentley RC, Barrett JC, et al. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res. 1998 Jun 15;58(12):2500-3. | PubMed